StemBioSys Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Crowdfunding

  • Latest Deal Amount
  • $71.8K

  • Investors
  • 7

StemBioSys General Information

Description

Developer of cell-matrix technologies designed for the enhanced isolation, growth, and delivery of stem cells or other difficult-to-culture cells for research, diagnostic, and therapeutic applications. The company's advanced stem cell culture system replicates the 3-dimensional environment in which stem cells naturally reside and proliferate while remaining small, proliferative, and undifferentiated. enabling healthcare professionals to provide therapeutics to patients for diseases such as adipose, bone marrow, umbilical cord blood, tissue, and cancer cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 3463 Magic Drive
  • Suite 110
  • San Antonio, TX 78229
  • United States
+1 (210)
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 3463 Magic Drive
  • Suite 110
  • San Antonio, TX 78229
  • United States
+1 (210)

StemBioSys Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

StemBioSys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Equity Crowdfunding 05-Sep-2024 $71.8K Completed Generating Revenue
10. Grant 03-Mar-2023 Completed Generating Revenue
9. Later Stage VC (Series C) 30-Sep-2021 Completed Generating Revenue
8. Later Stage VC 08-Dec-2020 Cancelled Generating Revenue
7. Debt - PPP 08-Apr-2020 Completed Generating Revenue
6. Later Stage VC 09-Jan-2020 Cancelled Generating Revenue
5. Later Stage VC (Series B) 15-May-2018 Completed Generating Revenue
4. Grant 01-Jan-2018 Completed Generating Revenue
3. Accelerator/Incubator 19-Sep-2017 $10.4M Completed Generating Revenue
2. Later Stage VC (Series A) 01-Apr-2015 $8M $10.4M Completed Startup
To view StemBioSys’s complete valuation and funding history, request access »

StemBioSys Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B
Series A 4,000,000 $0.100000 5% $2 $2 1x $2 27.91%
To view StemBioSys’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

StemBioSys Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cell-matrix technologies designed for the enhanced isolation, growth, and delivery of stem cells or other d
Biotechnology
San Antonio, TX
11 As of 2025

San Diego, CA
 

Redwood City, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

StemBioSys Competitors (8)

One of StemBioSys’s 8 competitors is Stemedica, a Venture Capital-Backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Stemedica Venture Capital-Backed San Diego, CA
Jasper Therapeutics Formerly VC-backed Redwood City, CA
CellPhire Therapeutics Venture Capital-Backed Rockville, MD
Vitro Biopharma Formerly VC-backed Denver, CO
Fate Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 8 competitors. Get the full list »

StemBioSys Patents

StemBioSys Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3130860-A1 Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds Pending 21-Feb-2019
EP-3927814-A1 Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds Pending 21-Feb-2019
JP-2023076502-A Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds Active 21-Feb-2019
JP-2024144465-A Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds Active 21-Feb-2019
US-11220671-B2 Methods for the maturation of cardiomyocytes on amniotic fluid cell-derived ecm, cellular constructs, and uses for cardiotoxicity and proarrhythmic screening of drug compounds Active 21-Feb-2019 C12N5/0657
To view StemBioSys’s complete patent history, request access »

StemBioSys Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

StemBioSys Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Barshop Ventures Family Office Minority
BioBridge Investment Bank Minority
Fountainhead Biomedical Holdings Venture Capital Minority
U.S. Department of Health and Human Services Government
Johnson & Johnson Innovation - JLABS Accelerator/Incubator Minority
You’re viewing 5 of 7 investors. Get the full list »

StemBioSys Acquisitions (1)

StemBioSys’s most recent deal was a Merger/Acquisition with CarTox. The deal was made on 08-Jan-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
CarTox 08-Jan-2020 Merger/Acquisition Decision/Risk Analysis
To view StemBioSys’s complete acquisitions history, request access »

StemBioSys FAQs

  • When was StemBioSys founded?

    StemBioSys was founded in 2010.

  • Where is StemBioSys headquartered?

    StemBioSys is headquartered in San Antonio, TX.

  • What is the size of StemBioSys?

    StemBioSys has 11 total employees.

  • What industry is StemBioSys in?

    StemBioSys’s primary industry is Biotechnology.

  • Is StemBioSys a private or public company?

    StemBioSys is a Private company.

  • What is the current valuation of StemBioSys?

    The current valuation of StemBioSys is .

  • What is StemBioSys’s current revenue?

    The current revenue for StemBioSys is .

  • How much funding has StemBioSys raised over time?

    StemBioSys has raised $21.7M.

  • Who are StemBioSys’s investors?

    Barshop Ventures, BioBridge, Fountainhead Biomedical Holdings, U.S. Department of Health and Human Services, and Johnson & Johnson Innovation - JLABS are 5 of 7 investors who have invested in StemBioSys.

  • Who are StemBioSys’s competitors?

    Stemedica, Jasper Therapeutics, CellPhire Therapeutics, Vitro Biopharma, and Fate Therapeutics are some of the 8 competitors of StemBioSys.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process